EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
Sep 12, 2018
|
EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors
Sep 10, 2018
|
EyePoint Pharmaceuticals Secures Pass-through Payment Status and Assignment of C-Code for DEXYCU™
Sep 05, 2018
|
EyePoint Pharmaceuticals Announces Fiscal 2018 Fourth Quarter & Full Year Financial Results Release Date and Conference Call Information
Sep 05, 2018
|
EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 28, 2018
|
EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality
Aug 15, 2018
|
EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 03, 2018
|
EyePoint Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
Aug 02, 2018
|
EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officer
Aug 01, 2018
|
EyePoint Pharmaceuticals Announces Presentation of Data Highlighting YUTIQ™ for Posterior Segment Uveitis at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
Jul 25, 2018
|
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
Jul 11, 2018
|
EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors
Jun 26, 2018
|
EyePoint Pharmaceuticals Announces Stockholder Approval of Second Tranche of Capital Financing
Jun 25, 2018
|
EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S.
May 16, 2018
|
EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results
May 08, 2018
|
EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Apr 19, 2018
|
EyePoint Pharmaceuticals' YUTIQ™ for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Apr 18, 2018
|
EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU™
Apr 12, 2018
|
pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company Will Rebrand as EyePoint Pharmaceuticals, Inc.
Mar 28, 2018
|
pSivida Announces FDA Acceptance For Filing of New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis
Mar 19, 2018
|